<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34284643</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1758-2032</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Neurodegenerative disease management</Title><ISOAbbreviation>Neurodegener Dis Manag</ISOAbbreviation></Journal><ArticleTitle>A survey on patients' disease perception and the impact of the COVID-19 pandemic on persons living with amyotrophic lateral sclerosis&#xa0;in Malaysia.</ArticleTitle><Pagination><StartPage>307</StartPage><EndPage>314</EndPage><MedlinePgn>307-314</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2217/nmt-2021-0004</ELocationID><Abstract><AbstractText><b>Aim:</b> To investigate the patients' perception of their disease, its management and the impact of the COVID-19 pandemic on persons living with amyotrophic lateral sclerosis (ALS) in Malaysia. <b>Patients &amp; methods:</b> An online survey comprising 42 questions was conducted on ALS patients during the peak of the COVID-19 pandemic. <b>Results:</b> Responses were received from 37/60 (62%) participants with ALS directly or through their caregivers. During the COVID-19 pandemic, two-thirds of patients were negatively impacted by the sudden disruption to their hospital appointments, rehabilitation sessions and reduced social interactions. <b>Conclusion:</b> This study provided insight into patients' perception of their care and management of ALS in Malaysia which will facilitate in implementing changes that can improve care to persons living with this devastating illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edgar</LastName><ForeName>Suzanna</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4275-2297</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abdul-Aziz</LastName><ForeName>Nur Adilah</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loh</LastName><ForeName>Ee Chin</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capelle</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goh</LastName><ForeName>Khean-Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latif</LastName><ForeName>Lydia Abdul</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shahrizaila</LastName><ForeName>Nortina</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-0031-7692</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad-Annuar</LastName><ForeName>Azlina</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6329-4366</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, 50603, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRGS/1/2018/SKK08/UM/01/1</GrantID><Agency>Malaysian Ministry of Education Fundamental Research Grant Scheme</Agency><Country/></Grant><Grant><GrantID>IF008-2019</GrantID><Agency>Amyotrophic Lateral Sclerosis Association</Agency><Country/></Grant><Grant><GrantID>IF012-2019</GrantID><Agency>Sydney Southeast Asia Centre</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurodegener Dis Manag</MedlineTA><NlmUniqueID>101517977</NlmUniqueID><ISSNLinking>1758-2024</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="Y">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Malaysia</Keyword><Keyword MajorTopicYN="N">disease management</Keyword><Keyword MajorTopicYN="N">motor neurone disease</Keyword><Keyword MajorTopicYN="N">survey</Keyword></KeywordList><CoiStatement><b>Financial &amp; competing interests disclosure</b>. N Shahrizaila receives funding support from the Malaysian Ministry of Education Fundamental Research Grant Scheme (FRGS/1/2018/SKK08/UM/01/1), Amyotrophic Lateral Sclerosis Association (IF008-2019) and Sydney Southeast Asia Center (IF012-2019). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>21</Day><Hour>5</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34284643</ArticleId><ArticleId IdType="pmc">PMC8320654</ArticleId><ArticleId IdType="doi">10.2217/nmt-2021-0004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zarei S, Carr K, Reiley L et al. A comprehensive review of amyotrophic lateral sclerosis. Surg. Neurol. Int. 6(171), (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4653353</ArticleId><ArticleId IdType="pubmed">26629397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC et al. Amyotrophic lateral sclerosis. Lancet 377(9769), 942&#x2013;955 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Van Den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol. 7(11), 639&#x2013;649 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21989247</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhaskar S, Bradley S, Israeli-Korn S et al. Chronic neurology in COVID-19 era: clinical considerations and recommendations from the REPROGRAM consortium. Front. Neurol. 11(664), 1&#x2013;13 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7339863</ArticleId><ArticleId IdType="pubmed">32695066</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams J, Lee M, Peng W. Critical review of complementary and alternative medicine use in amyotrophic lateral sclerosis: prevalence and users' profile, decision-making, information seeking, and disclosure in the face of a lack of efficacy. Neurodegener. Dis. 18(4), 225&#x2013;232 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30248676</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasner M, Klier H, Borasio GD. The use of alternative medicine by patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 191(1&#x2013;2), 151&#x2013;154 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11677007</ArticleId></ArticleIdList></Reference><Reference><Citation>Motor Neurone Disease Association. Examining the impact of the COVID-19 pandemic on people with MND (2020). www.mndassociation.org/research/get-involved-in-research/take-part-in-research/impact-of-covid-19-survey/</Citation></Reference><Reference><Citation>Hogden A, Foley G, Henderson RD, James N, Aoun SM. Amyotrophic lateral sclerosis: improving care with a multidisciplinary approach. J. Multidiscip. Healthc. 10, 205&#x2013;215 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446964</ArticleId><ArticleId IdType="pubmed">28579792</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooney J, Byrne S, Heverin M et al. A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland. J. Neurol. Neurosurg. Psychiatry 86(5), 496&#x2013;501 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25550416</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Berg JP, Kalmijn S, Lindeman E et al. Multidisciplinary ALS care improves quality of life in patients with ALS. Neurology 65(8), 1264&#x2013;1267 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16247055</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Abrahams S, Borasio GD et al. EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force. Eur. J. Neurol. 19(3), 360&#x2013;375 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21914052</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan W, Chen X, Bao J et al. The use of integrative therapies in patients with amyotrophic lateral sclerosis in Shanghai, China. Eviden. Based Complement. Alternat. Med. 2013, 613596 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3865630</ArticleId><ArticleId IdType="pubmed">24363770</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Mun S, Park J, Choi S, Lee S, Kim S. Complementary and Alternative Medicine Use in Amyotrophic Lateral Sclerosis Cases in South Korea. Eviden. Based Complement. Alternat. Med. 2019, 4217057 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6683772</ArticleId><ArticleId IdType="pubmed">31428170</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdul-Aziz NA, Toh TH, Goh KJ et al. Natural history and clinical features of ALS in Malaysia. Amyotroph. Lateral Scler. Frontotemporal. Degener. 22(1-2), 108&#x2013;116 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33084408</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae JS, Hong YH, Baek W et al. Current status of the diagnosis and management of amyotrophic lateral sclerosis in Korea: a multi-center cross-sectional study. J. Clin. Neurol. 8(4), 293&#x2013;300 (2012).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3540289</ArticleId><ArticleId IdType="pubmed">23323138</ArticleId></ArticleIdList></Reference><Reference><Citation>Braga AC, Gromicho M, Pinto S, De Carvalho M, Henning F. A comparative study of South African and Portuguese amyotrophic lateral sclerosis cohorts. J. Neurol. Sci. 414, 116857 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32339966</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorst J, Chen L, Rosenbohm A et al. Prognostic factors in ALS: a comparison between Germany and China. J. Neurol. 266(6), 1516&#x2013;1525 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30923935</ArticleId></ArticleIdList></Reference><Reference><Citation>Deloitte Access Economics. Economics analysis of Motor Neurone Disease in Australia. Report for Motor Neurone Disease Australia, Deloitte Access Economics, Canberra (2015). www.mndaust.asn.au/Discover-our-research/Latest-research/Statistics</Citation></Reference><Reference><Citation>Tew CW, Tan LF, Luo N, Ng WY, Yap P. Why family caregivers choose to institutionalize a loved one with dementia: a Singapore perspective. Dement. Geriatr. Cogn. Disord. 30(6), 509&#x2013;516 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21252545</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu L, Shyu WC, Liu YH, Wang SP, Chang TP. Factors determining the attitudes of family caregivers of dementia patients toward nursing home placement in Taiwan: comparisons between urban and semiurban areas. Public Health Nurs. 18(4), 281&#x2013;291 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11468068</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO). Coronavirus Disease 2019 (COVID-19): situation report (2020). www.who.int/docs/default-source/coronaviruse/situation-reports/20200404-sitrep-75-covid-19.pdf?sfvrsn=99251b2b_2</Citation></Reference><Reference><Citation>Glasmacher SA, Larraz J, Mehta AR et al. The immediate impact of the COVID-19 pandemic on motor neuron disease services and mortality in Scotland. J. Neurol. 268(6), 2038&#x2013;2040 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474506</ArticleId><ArticleId IdType="pubmed">32889618</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>